Beranda › Karsinoma Sel Skuamosa Kepala dan Leher › Florida › Orlando
Uji klinis Karsinoma Sel Skuamosa Kepala dan Leher di Orlando, FL
16 studi untuk Karsinoma Sel Skuamosa Kepala dan Leher mencari peserta di lokasi sekitar Orlando (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #48, Celebration · 17 mi jauhnya
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Menerima pesertaFase 3
- AdventHealth Medical Group Oncology and Hematology at Orlando, Orlando
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Menerima pesertaFase 3
- AdventHealth Orlando, Orlando
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Menerima pesertaFase 1
- Sara Cannon Research Institute Lake Nona, Orlando
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Menerima pesertaFase 1/2
- Florida Cancer Specialists - Lake Nona, Orlando
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Menerima pesertaFase 2
- Orlando Health, Orlando
SMP-3124LP in Adults With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Advent Health, Celebration · 17 mi jauhnya
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Menerima pesertaFase 1/2
- Clermont Oncology Center, Clermont · 24 mi jauhnya
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute (Lake Nona), Orlando
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Menerima pesertaFase 1
- Florida Cancer Specialists - Lake Nona, Orlando
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Menerima pesertaFase 1
- Florida Cancer Specialists, Orlando
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Menerima pesertaFase 3
- AdventHealth Medical Group Oncology & Hematology at Orlando, Orlando
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Florida Cancer Specialists-Lake Nona, Orlando
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Menerima pesertaFase 1
- Dren Investigational Site, Orlando
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Research Site 137, Orlando
- Research Site 118, Celebration · 17 mi jauhnya
Uji klinis Karsinoma Sel Skuamosa Kepala dan Leher di kota lain
- Houston, TX47 studi
- Los Angeles, CA42 studi
- Boston, MA40 studi
- New York City, NY39 studi
- Nashville, TN39 studi
- St. Louis, MO28 studi
- Arlington, VA26 studi
- Chicago, IL26 studi
- Philadelphia, PA26 studi
- Atlanta, GA24 studi
- San Antonio, TX22 studi
- Pittsburgh, PA22 studi
Studi lain di Orlando
- Kanker Paru Non-Sel Kecil44 studi
- Obesitas32 studi
- Kanker Metastatik29 studi
- Kelebihan Berat Badan27 studi
- Penyakit Alzheimer25 studi
- Diabetes Tipe 225 studi
- Kanker (semua jenis)24 studi
- Kanker Payudara23 studi
- Kanker Ovarium22 studi
- Kolitis Ulseratif22 studi
- Kanker Paru21 studi
- Kanker Kolorektal19 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.